Clinical Trial Update: SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of SHR-A1811 Injection for platinum-sensitive recurrent ovarian cancer is listed, with the trial status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SHR-A1811 Injection (A1811)

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING